US Stock MarketDetailed Quotes

GNPX Genprex

Watchlist
  • 0.4409
  • -0.0301-6.39%
Close Feb 14 16:00 ET
  • 0.4231
  • -0.0178-4.04%
Post 19:59 ET
3.75MMarket Cap-0.04P/E (TTM)

About Genprex Company

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Company Profile

SymbolGNPX
Company NameGenprex
Listing DateMar 29, 2018
Issue Price5.00
Founded2009
CEOMr. Ryan M. Confer
MarketNASDAQ
Employees26
Fiscal Year Ends12-31
Address3300 Bee Cave Road,Suite 650-227
CityAustin
ProvinceTexas
CountryUnited States of America
Zip Code78746
Phone1-877-774-4679

Company Executives

  • Name
  • Position
  • Salary
  • Ryan M. Confer
  • Director, President, Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Mark S. Berger, M.D.
  • Chief Medical Officer
  • 947.11K
  • Jose Antonio Moreno Toscano
  • Independent Director
  • 161.61K
  • William R. Wilson, Jr
  • Independent Director
  • 151.16K
  • Brent Longnecker
  • Independent Director
  • 161.61K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.